Glioblastoma Multiforme Market Size Share Analysis 2022-2029

Increasing Burden of Brain and Other Nervous System Cancers

The increasing burden of the brain and nervous system cancer from the last decade has boosted the market growth in the forecast period. The fast-growing type of CNS tumor forms from the glial tissue of the brain and the spinal cord, and it has cells that look very different from the normal cells. Glioblastoma usually occurs in adults and affects their brain more often than their spinal cord. The rate of new brain and other nervous system cancer cases was 6.4 per 100,000 men and women per year. The death rate was 4.4 per 100,000 men and women per year. These rates are age-adjusted and based on 2014–2018 cases. According to US government statics, 0.6 percent of men and women are treated with brain and CNS cancer at some point during their life, based on 2016–2018 data. The three countries with the highest number of incident cases were China, the USA, and India. CNS cancer was responsible for 7·7 million. Thus these three countries are more affected with Glioblastoma Multiforme. In December 2017, the Health Ministry in Japan approved the recommendation of the Central Social Insurance Medical Council or "Chuikyo" for providing reimbursement for Novocure's Optune, which is a non-invasive, portable device in the treatment of newly diagnosed glioblastoma.

Increasing Us Fda Approval Of New Drugs

The FDA is also approving many drugs which passed the clinical trials for the patients' uses. According to the CNS Pharmaceuticals, Inc., a trial evaluating the product's efficacy in adults with GBM have progressed on the frontline treatment started in the first quarter of 2021. The trial will undergo some modifications based on the communication between the FDA and the company. For instance, now, the primary endpoint of the trial is overall survival.

Additionally, pharmaceutical companies are developing new drugs and therapies to maintain their advantage over their competitors and establish them in the regional market. For instance, in December 2017, Genentech announced that it had received approval from the U.S. FDA for Avastin (bevacizumab) to be used to treat glioblastoma in adults.

In September 2017, the FDA approved Amgen MVASI, the first bevacizumab biosimilar and the first anti-cancer biosimilar to be approved for treating five types of cancer, including GBM. 

The FDA  has approved the chemotherapy agent Temodar for the initial treatment of glioblastoma multiforme. The new approval indicates that Temodar should be used during radiation therapy and following radiation therapy in newly diagnosed patients. Temodar was previously FDA-approved to treat recurrent astrocytoma.

Strong R&D Initiatives From Key Players

The key players' intense research and development initiative is also driving the market growth in the forecast period. Sun Pharmaceutical Industries, Ltd, Teva Pharmaceutical Industries, Ltd, Arbor Pharmaceuticals LLC., Bexion Pharmaceuticals, LLC, F. Hoffmann-La, are prominent players in this market Roche AG., Merck & Co., Inc., and others.

For instance, Moon Shot has successfully developed Delta-24-RGD, a cold virus engineered to infect and attack glioblastoma cells. Researchers explore the possibility of delivering the virus directly to the tumor using the stem cells derived from the bone marrow abbreviated mesenchymal stem cells (MSCs).

Continue a Phase I trial to determine appropriate treatment doses and validate the efficiency and ability to use MSCs to deliver the virus to glioblastomas.

Genomic and proteomic scale analysis can identify proteins and pathways involved in developing chemotherapeutic resistance mechanisms responsible for recurrent disease. With the advent of the TCGA (The Cancer Genome Atlas) resources, genomic analysis of cancers is at the forefront of drug discovery.  The novel proteomic techniques in the last decade, with the resources allocated to address the lack of a cure for GBM, will accelerate the discovery of a treatment and shed light on the feasibility of precision medicine.

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com